- Singular Genomics Systems ( NASDAQ: OMIC ) has reported its instrument shipments and preliminary unaudited Q422 revenue.
- The company shipped five G4 instruments through December 31, 2022 and recognized ~$700K in preliminary unaudited revenue during the Q422 vs consensus of $650.37K .
-
“We are pleased to have finished the year on a strong note. We executed to our plan in Q4, shipping several G4 systems which are now installed and running in customer labs.In 2023, we will remain focused on scaling production of G4 instruments, expanding our customer base, and advancing development of our product roadmap,” said Drew Spaventa, Chairman and Chief Executive Officer.
For further details see:
Singular Genomics reports instrument shipments and preliminary unaudited Q4 revenue